In the first three quarters of the year, Jointown's operating income, net profit attributable to the parent company, and net profit attributable to the parent company after deducting non-recurring profit and loss reached RMB 113.429 billion, RMB 1.696 billion and RMB 1.630 billion, respectively.

On April 16, Jointown announced that the Pre-REITs real estate private equity investment fund has completed registration and fundraising, with the initial capital of RMB 826 million fully paid in, laying a solid foundation for the company's subsequent asset securitization work.

On 21 March, the State Council Information Office held a routine policy briefing to explain the Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High quality Development of the Traditional Chinese Medicine Industry. This policy is crafted with a top-level approach across all stages of the entire chain, proposing 21 tasks in 8 areas, focusing on improving quality, deepening reforms, and balancing tradition with innovation to inject strong momentum into the tradi

On January 4, 2025, two data assets, under the name of Jointown Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jointown"), namely, "Smart Pharmaceutical Sales Recommendation Service" and "Pharmaceutical Market Insight Service Report", successfully obtained the data property registration certificate issued by Shenzhen Data Exchange, marking a new breakthrough in the registration of Jointown data property rights.